Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
0.95% $3.18
America/New_York / 19 apr 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 51.58 mill |
EPS: | -1.710 |
P/E: | -1.860 |
Earnings Date: | May 09, 2024 |
SharesOutstanding: | 16.22 mill |
Avg Daily Volume: | 0.160 mill |
RATING 2024-04-19 |
---|
B- |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Neutral | |
Return On Equity: | Strong Sell | |
Return On Asset: | Sell | |
DE: | Neutral | |
P/E: | Sell | |
Price To Book: | Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | n/a | n/a | n/a | |||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -1.860 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.32x |
Company: PE -1.860 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$0.704 (-77.85%) $-2.48 |
Date: 2024-04-20 |
Expected Trading Range (DAY) |
---|
$ 2.84 - 3.52 ( +/- 10.79%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-08 | Mack Gene | Buy | 200 000 | Employee Stock Option (right to buy) |
2024-04-05 | Mack Gene | Buy | 0 | |
2024-03-28 | Riley Jeffrey Scott | Buy | 30 000 | Common Stock |
2024-03-26 | Alder Matthias | Sell | 18 750 | Restricted Stock Units |
2024-03-26 | Alder Matthias | Buy | 637 | Common Stock |
INSIDER POWER |
---|
86.87 |
Last 62 transactions |
Buy: 1 996 906 | Sell: 408 942 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $3.18 (0.95% ) |
Volume | 0.0714 mill |
Avg. Vol. | 0.160 mill |
% of Avg. Vol | 44.50 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. It is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases. The company was founded in 2017 and is based in Bethesda, Maryland.